Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at JPMorgan Chase & Co. from $168.00 to $200.00. They now have an "overweight" rating on the stock.
Ascendis Pharma A/S - American Depositary Shares (ASND)
Last ascendis pharma a/s - american depositary shares earnings: 11/18 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ascendispharma.com
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
ASND
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ASND alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ASND alerts
High impacting Ascendis Pharma A/S - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ASND
News
- OMass Therapeutics appoints Birgitte Volck as Non-Executive DirectorGlobeNewswire
- Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at Cantor Fitzgerald from $170.00 to $200.00. They now have an "overweight" rating on the stock.MarketBeat
- Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care ConferenceGlobeNewswire
- Ascendis Pharma A/S (NASDAQ: ASND) was given a new $180.00 price target on by analysts at Morgan Stanley.MarketBeat
- FIRST AND ONLY TREATMENT FOR CHRONIC HYPOPARATHYROIDISM APPROVED IN AUSTRALIA [Yahoo! Finance]Yahoo! Finance
ASND
Earnings
- 2/12/25 - Beat
ASND
Sec Filings
- 3/20/25 - Form 6-K
- 3/12/25 - Form 6-K
- 3/7/25 - Form 144
- ASND's page on the SEC website